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Background: Baroreflex Activation Therapy (BAT) has demonstrated therapeutic benefit over >5 years in small cohorts. The randomized, controlled 
Rheos Pivotal Trial of BAT provided evidence of therapy benefit and safety in resistant hypertension patients through 12 months.
Methods: All patients enrolled in the Rheos Pivotal Trial were eligible to participate in long-term follow-up. Patients qualified as responders by 
fulfilling one or more criteria established by the US Food and Drug Administration: achieving and maintaining goal blood pressure, persistently 
reducing systolic blood pressure (SBP) ≥ 20 mmHg, increasing SBP ≥ 20 mmHg following device deactivation, developing hypertensive crisis 
(hospitalization SBP > 220 mmHg) following device deactivation, or receiving approval for Compassionate Use due to clear evidence of benefit.
Results: Of the 322 patients implanted in the Rheos Pivotal Trial, 244 (76%) qualified as responders. An additional 10 patients (3%) did not 
participate in long-term follow-up but otherwise fulfilled responder criteria. Over an average follow-up of 28 ± 9 months (max 53 months), blood 
pressure reductions among all those implanted were maintained relative to the long-term efficacy time point at 12 months.
Screening (N=322) Pre-Implant (N=322) Month 12 (N=294) Last Follow-up (N=271)
Systolic BP (mm Hg) 183 ± 16 178 ± 23 143 ± 29* 143 ± 28*
Diastolic BP (mm Hg) 105 ± 12 103 ± 15 87 ± 17* 87 ± 18*
Medications Not applicable 5.2 ± 1.9 4.6 ± 1.9* 5.0 ± 2.0†
Values: Mean ± SD *p < 0.05 vs. Pre-Implant †p < 0.05 vs. Month 12
Conclusions: The efficacy of BAT demonstrated in the Rheos Pivotal Trial is maintained up to 4 years in a large population. This corroborates 
previous findings that the therapeutic benefit persists in the long term.
